A phase II study of perioperative pembrolizumab plus mFOLFOX in patients with potentially resectable esophagus, gastroesophageal junction (GEJ), and stomach adenocarcinoma.

Weijing Sun, Nirmal Veeramachaneni,Raed Al-Rajabi,Rashna Madan,Anup Kasi,Mazin Al-Kasspooles,Joaquina Baranda,Anwaar Saeed,Milind A Phadnis,Andrew K Godwin,Mojtaba Olyaee,Natalie Streeter,Alykhan Nagji,Junqiang Dai,Stephen Williamson

Cancer medicine（2023）

引用 1|浏览19

暂无评分

摘要

The perioperative pembrolizumab and mFOLFOX combination in resectable esophageal/gastric/GEJ adenocarcinoma is very effective with 90% ypRR, 21% ypCR, and impressive long-time survival benefits.

查看译文

关键词

adenocarcinoma, CD8, esophageal gastric, GEJ, immune checkpoint inhibitor (ICI), pathological response (ypRR), PD-L1, pembrolizumab, perioperative, tumor regression score (TRS)

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要